Compare DuPont de Nemours Inc (DD) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DuPont de Nemours Inc vs Smith & Nephew plc — how do they compare? DuPont de Nemours Inc trades at $132.05 (market cap $17.70B), while Smith & Nephew plc trades at $27.08 (market cap $11.31B). The key difference: DuPont de Nemours Inc is the larger of the two by market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold DuPont de Nemours Inc for 89 Days and Smith & Nephew plc for 120 Days on average.
| DD | SNN | |
|---|---|---|
Market Cap | $17.70B | $11.31B |
Volume | 638,303 | 1,050,005 |
Sector | Basic Materials | Health |
52-Week High | $154.59 | $37.17 |
52-Week Low | $92.49 | $26.42 |
Typical Hold Time | 89 Days | 120 Days |
Enterprise Value | $19.09B | $14.35B |
Dividend Yield | 1.83% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DuPont (DD) trades at $132.48, down 0.6% for the day, with neutral technical signals and mixed fundamentals. The company has beaten earnings estimates for three consecutive quarters but shows declining revenue and negative net income for 2025. Recent innovations include digital tools for sugar separation and sustainable Tyvek materials, while facing legal settlements over PFAS contamination.
Outlook remains cautious with analyst consensus favoring Buy (58.5%) but a price target of $95 below current levels. Key opportunities include margin expansion in healthcare and water technologies, while risks involve ongoing litigation costs, uneven construction demand, and profitability challenges despite recent earnings beats.
SNN trades at $26.96, near its 52-week low, with a bearish technical signal. The company has shown improving fundamentals, with revenue growing from $5.2B in 2022 to $6.16B in 2025 and net income margin expanding to 10.08%. Recent product launches, like the EVOS PELVIC System, highlight innovation, but the stock faces negative sentiment from analyst downgrades and CFO departure news.
The outlook is mixed: strong profitability and cash flow support value, but bearish technicals and cautious analyst consensus (26% buy, 65% hold) suggest limited near-term upside. Key risks include execution challenges and competitive pressures. Investors should weigh solid fundamentals against weak market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DuPont de Nemours Inc
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
